pharmaphorum
MARCH 19, 2021
The pandemic has ushered in a number of major changes to healthcare systems, notably in the ways in which pharmaceutical companies communicate, visit and engage with physicians. Florent Edouard is the global head of commercial excellence at Grünenthal Group , a pharmaceutical company headquartered in Germany and specialised in pain.
European Pharmaceutical Review
JULY 7, 2022
Dr Eric Hughes joins Teva with experience in all phases of drug development at global pharmaceutical companies, most recently Boston-based Vertex Pharmaceuticals, which he joined last year. He will be based out of Teva’s US headquarters in Parsippany, New Jersey. . Dr Hughes earned his MD and PhD at Yale School of Medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 18, 2020
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.
European Pharmaceutical Review
MARCH 11, 2024
For example, rising ambient temperatures and ingress of mould from items entering cleanrooms, has resulted in some vaccine and pharmaceutical companies in Europe experiencing increased contamination. Ahmed et al.
pharmaphorum
MARCH 2, 2021
The Conservative Party has strong ties with pharma and life sciences and has been backing the industry since David Cameron led it back to power in 2010 with a range of policies aimed at boosting research and investment.
European Pharmaceutical Review
APRIL 8, 2024
A study investigating the trend for existing pharmaceutical companies to outsource to contracted development and manufacturing organisations (CDMOs), analysing the position of companies manufacturing monoclonal antibody drugs (mAbs). Yoshiura et al. Yoshiura et al.
Pharmaceutical Technology
MAY 17, 2023
Swiss pharmaceutical company IDEOGEN will be responsible for commercialising Glassia in the country. To ensure wide access to eligible patients, we are excited to partner with the IDEOGEN Group, a company focused on the commercialisation of speciality medicines for rare diseases across Europe.”
Expert insights. Personalized for you.
141 
Let's personalize your content